KYUNG NAM PHARM CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,235 KRW | -.--% |
|
+2.49% | -26.58% |
| 2023 | Kyung Nam Pharm Co.,Ltd. announced that it has received KRW 5 billion in funding | CI |
| 2023 | Kyung Nam Pharm Co.,Ltd. announced that it expects to receive KRW 5 billion in funding | CI |
| Sales 2022 | 59B 43.25M | Sales 2023 | 68.45B 50.17M | Capitalization | 59.87B 43.88M |
|---|---|---|---|---|---|
| Net income 2022 | -6.78B -4.97M | Net income 2023 | -21B -15.39M | EV / Sales 2022 | 1.19 x |
| Net cash position 2022 | 12.28B 9M | Net Debt 2023 | 16.32B 11.96M | EV / Sales 2023 | 1.11 x |
| P/E ratio 2022 |
-11.5
x | P/E ratio 2023 |
-2.84
x | Employees | 230 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 70.94% |
More Fundamentals
* Assessed data
More news
| 1 week | +2.49% | ||
| Current month | -5.07% | ||
| 1 month | -5.07% | ||
| 3 months | -5.73% | ||
| 6 months | +6.74% | ||
| Current year | -26.58% |
1 week
1 191.00
1 244.00
1 month
1 162.001 444.00
Current year
1 162.001 753.00
1 year
1 135.002 515.00
3 years
1 135.009 740.00
5 years
1 135.0017 750.00
10 years
1 135.0018 600.00
| Managers | Title | Age | Since |
|---|---|---|---|
Seong-Won Oh
CEO | Chief Executive Officer | 46 | - |
Seung-Jae Lim
AUD | Comptroller/Controller/Auditor | 77 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Byung-Jin Kim
BRD | Director/Board Member | 46 | - |
Seong-Won Oh
CEO | Chief Executive Officer | 46 | - |
Hyeon-Bo Yoon
BRD | Director/Board Member | 53 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-02 | 1,219 | -1.30% | 227,198 |
| 24-04-30 | 1,235 | -.--% | 130,778 |
| 24-04-29 | 1,235 | +3.43% | 434,903 |
| 24-04-26 | 1,194 | -0.50% | 125,415 |
| 24-04-25 | 1,200 | -0.08% | 104,629 |
End-of-day quote Korea S.E., April 29, 2024
More quotes
KYUNG NAM PHARM.CO., LTD. is a Korea-based company mainly engaged in the manufacture and sale of pharmaceuticals. The Company's product portfolio consists of vitamin products, placenta products, health food products and general pharmaceuticals. The Company provides vitamin products under the brand name LEMONA. It supplies health food products such as lactobacillus products through convenient stores and marts. The placenta products include human placenta related injections and drinks. The general pharmaceuticals include athlete foot therapeutic agents, inflammatory drugs, cold remedies, multi-nutrients and others.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -26.58% | 31.77M | |
| +20.61% | 43.18B | |
| +20.67% | 22.59B | |
| +14.56% | 14.56B | |
| +13.94% | 13.54B | |
| +43.35% | 11.5B | |
| -8.37% | 6.93B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +10.21% | 5.36B |
- Stock Market
- Equities
- A053950 Stock
